Domestically produced novel drugs accounted for more than 80 per cent of market approvals in China in the first half of the year, reflecting a “leap” in the quality of the country’s pharmaceutical innovation, according to a government spokesman. A total of 38 innovative drugs…
This story was indexed from the original publisher.
Read at South China Morning Post